lexaria glp 1 Bio ( #LEXX) just completed dosing in its next‑gen GLP‑1 animal study using DehydraTECH with amycretin and retatrutide, targeting better oral delivery and tolerability. #LEXX #Biotech #GLP1 #Obesity #Diabetes #SmallCaps https://prismmarketview Lexaria Bioscience (@LexariaBioCorp) / Posts

Survey reports are just one of the many helpful products and services included with an International Foundation membership.

The 'Switch' is On: Proving the Viability of Oral Maintenance Therapy The ATTAIN-MAINTAIN study was a first-of-its-kind Phase 3 trial designed to answer a critical clinical question: can patients who have successfully lost weight on injectable GLP-1s (Wegovy or Zepbound) switch directly to an oral agent and maintain their results

Q: If BPC-157 is genuinely promising, why hasn't a proper trial been done

PT-141 nasal spray delivers bremelanotide through the nasal mucosa, where the peptide absorbs directly into systemic circulation bypassing first-pass metabolism like injectable administration but with significantly lower bioavailability (~30% nasal vs ~80-100% subcutaneous)